Step 3: Sanofi com­mits up to $100M to opt-in on Al­ny­lam’s PhI­II RNAi he­mo­phil­ia tri­al

John Maraganore, Al­ny­lam

Al­ny­lam is step­ping up to the start­ing line for a Phase III study of its he­mo­phil­ia drug fi­tusir­an with Sanofi on board as a part­ner. The phar­ma com­pa­ny lined up the opt-in rights un­der their ear­li­er deal to buy a mi­nor­i­ty stake in the biotech for $700 mil­lion. And Sanofi is now com­mit­ted to pro­vid­ing $75 mil­lion in de­vel­op­ment and reg­u­la­to­ry mile­stones fol­low­ing a $25 mil­lion up­front due when Phase III starts in ear­ly 2017.

Cam­bridge, MA-based Al­ny­lam $AL­NY and its col­lab­o­ra­tor Sanofi $SFY will now part­ner up on de­vel­op­ment of the RNAi pro­gram with the prospect of a mar­ket­ing al­liance in the US, Cana­da and West­ern Eu­rope, while Sanofi Gen­zyme in Boston will have rights to de­vel­op the drug for he­mo­phil­ia and rare bleed­ing dis­or­ders in the rest of the world.

Ex­ecs from both sides her­ald­ed the move as an­oth­er big step for­ward for an al­liance an­nounced with great fan­fare in ear­ly 2014, which great­ly ex­pand­ed an ex­ist­ing re­la­tion­ship. For Sanofi, the Al­ny­lam deal re­flect­ed their en­thu­si­asm for a sim­i­lar re­la­tion­ship they have with Re­gen­eron, which has been their most pro­duc­tive pact.

Sanofi Gen­zyme, though, is leav­ing an­oth­er pro­gram on the side­line at Al­ny­lam. There will be no opt-in for ALN-AS1, an­oth­er RNAi drug aimed at acute he­pat­ic por­phyr­ias. Sanofi bowed out af­ter tak­ing a look at the da­ta from the first two stages of a Phase I study. A third stage is com­ing up for re­view as Al­ny­lam plans to pro­ceed on its own.

The opt-in on he­mo­phil­ia comes as a boon to Al­ny­lam, which had to scrap the num­ber two drug in its pipeline — re­vusir­an — af­ter track­ing a dis­pro­por­tion­ate num­ber of deaths on the treat­ment arm of a late-stage pro­gram. On a brighter note, Al­ny­lam part­ner The Med­i­cines Com­pa­ny en­joyed a clin­i­cal suc­cess with their PC­SK9 drug.

Al­ny­lam CEO John Maraganore had this to say:

“This de­ci­sion al­lows us to broad­en the glob­al reach and ac­cel­er­ate the com­mer­cial de­vel­op­ment of fi­tusir­an, a po­ten­tial­ly trans­for­ma­tive ap­proach to the treat­ment of he­mo­phil­ia and rare bleed­ing dis­or­ders, with a well-es­tab­lished part­ner in Sanofi Gen­zyme. We look for­ward to con­tin­ued col­lab­o­ra­tion with Sanofi Gen­zyme to ad­vance fi­tusir­an as Al­ny­lam tran­si­tions to­ward the com­mer­cial stage with our late-stage pipeline.”

In­side Track: Be­hind the Scenes of a Ma­jor Biotech SPAC

Dr. David Hung and Michelle Doig are no strangers to the SPAC phenomenon. As Founder and CEO of Nuvation Bio, a biotech company tackling some of the greatest unmet needs in oncology, Dr. Hung recently took the company public in one of this year’s biggest SPAC related deals. And as Partner at Omega Funds, Doig not only led and syndicated Nuvation Bio’s Series A, but is now also President of the newly formed, Omega-sponsored, Omega Alpha SPAC (Nasdaq: OMEG; oversubscribed $138m IPO priced January 6, 2021).

Hal Barron, GSK R&D chief (Endpoints News)

Hal Bar­ron gam­bles $625M cash on high-wire TIG­IT act, throw­ing Glax­o­SmithK­line in­to heat­ed race and com­plet­ing next-gen I/O trin­i­ty

Count Hal Barron and GlaxoSmithKline in for the TIGIT fight.

The stakes are as high as the risks: While a growing pack of Big Pharma rivals is lending credence to the hypothesis that TIGIT will be the next big immune checkpoint and cancer drug target, the first clinical trials have shown response rates that can be described as modest at best. But Barron’s bet is on the whole “axis” that the receptor sits on, with an eye on testing its new anti-TIGIT antibody not just in combo with PD-1 but also in triplets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

As Covid-19 shifts the world's at­ten­tion to biotech, Noubar Afeyan's Flag­ship builds $3.4B fund to fu­el new in­ven­tions. Here's the plan

A little more than a year ago, Flagship Pioneering rolled out a monster fund with $1.1 billion in it to bankroll the platform companies they were creating inside their own labs. But it turns out, that was just the prelude to a much, much larger raise, as both current investors — who’ve been reaping the rewards of some booming biotech stocks — join in with new investors betting on more in the years to come.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bio­gen sig­nals a big PhI­II fail­ure as the lead gene ther­a­py in their $800M Night­star buy­out goes down in flames

That $800 million buyout of Nightstar has turned into a bust for Biogen as the lead therapy in the deal failed a pivotal study, signaling a severe setback for the biotech’s ambitions in gene therapies.

The big biotech put out the word after the market closed on Monday that the gene therapy they picked up in the deal for a degenerative blindness called choroideremia failed the Phase III study, just a month after their #2 drug in the deal also flopped in a mid-stage study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

Geoffrey Porges, SVB Leerink

Top an­a­lyst maps a rocky road for Ver­tex — un­less they adopt a $10B M&A cam­paign to save the pipeline

After repeatedly poking Vertex $VRTX execs with pointed criticism of their R&D strategy, top SVB Leerink analyst Geoffrey Porges is now turning up the heat to a full-scale roasting.

In a note out early Monday morning, Porges spotlights the impact of Vertex’s recent follow-up failure on AATD — their treatment hit the endpoint but missed on commercial prospects — rewriting his recommended scenario for CEO Reshma Kewalramani as she grapples with the setback.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

Stephen Hahn (AP Images)

UP­DAT­ED: Ex-FDA com­mish Stephen Hahn joins Flag­ship, a ven­ture group that spawned Covid-19 vac­cine mak­er Mod­er­na

That revolving door between the FDA and industry is spinning even faster than usual.

Former FDA commissioner Stephen Hahn is joining Flagship Pioneering, the venture outfit that founded Moderna — which raced its way to an FDA EUA for a Covid-19 vaccine that is making billions of dollars– as the new CMO of its Preemptive Medicine and Health Security initiative.

Flagship confirmed the hire — first reported in The Washington Post — in a statement out late Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

Patrizia Cavazzoni, CDER

FDA’s Cavaz­zoni calls for ad­comms to ‘get back to the sub­stance’

While her comments were recorded prior to the FDA’s recent approval of Biogen’s controversial Alzheimer’s drug, CDER Director Patrizia Cavazzoni presciently called for substantiating reforms to the advisory committee process at the agency.

Short on examples, Cavazzoni said at a BIO event aired on Monday that some recent adcomms show “how they can be swayed by emotion in the face of hard facts,” but they need to “get back to the fundamentals, which is listening to thoughtful input from experts in response to thoughtful questions that we ask them.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Terns Phar­ma­ceu­ti­cals touts safe­ty da­ta from an ex-Eli Lil­ly can­di­date in the hunt for NASH treat­ment

While many others have tried — and failed — to get a NASH candidate across the finish line, Terns Pharmaceuticals thinks its FXR agonist will eventually earn its wings without the safety issues that have slowed others down. Now, a mid-stage safety readout could help add some validity to those hopes.

No patients in the Phase IIa LIFT study discontinued TERN-101 due to side effects, CMO Erin Quirk said during a call with investors on Monday morning. That includes pruritus, an uncomfortable itching sensation that frequently leads patients to drop out of other FXR agonist studies.

Paul Burton, incoming Moderna CMO (J&J/file photo)

Look­ing be­yond the pan­dem­ic, Mod­er­na ap­points J&J vet­er­an Paul Bur­ton as new CMO

Moderna is turning to one of its Covid-19 vaccine competitors to fill its open CMO slot, but this time, it’s not the vaccine experience they’re after.

Paul Burton, who’s spent 16 years at J&J, most recently as chief global medical affairs officer of Janssen, will take over as Moderna CMO on July 6.

With an eye toward a future beyond the pandemic, the mRNA biotech went with Burton, who earned his MD and PhD degrees in London, as he offers experience on a range of therapeutic areas, as well as work as a cardiothoracic surgeon and leading tech projects with Apple.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.